Loading: 100%
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reasons:
- It is not known how cost items are reported in the original P&L
- Not all line items from the original statement have been associated with a standardised figure (21 items missing)
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Clinical laboratory services
44
53
59
56
59
63
71
Product revenues
43
42
38
33
33
32
30
Royalty and license fee income
10
7
6
5
4
2
2
Total revenues
97
102
103
94
96
98
103
Cost of clinical laboratory services
30
32
36
38
39
40
43
Cost of product revenues
23
22
20
17
15
15
14
Research and development
10
8
6
4
3
3
4
Selling, general, and administrative
48
45
48
44
42
41
44
Provision for uncollectible accounts receivable
3
4
5
4
3
2
2
Legal fee expense
2
4
4
6
7
9
6
The amount of expense provided in the period pertaining to litigation settlement and related costs incurred on or before the balance sheet date pertaining to resolved, pending or t
4
0
0
0
0
0
0
Legal settlements, net
0
0
0
0
-3
-11
-57
Impairment charges
0
0
25
0
0
0
0
Total operating expenses
119
115
144
113
106
99
56
Operating loss
-22
-13
-40
-19
-10
-1
47
Interest
0
0
0
0
0
0
0
Other
0
0
0
0
0
0
0
Foreign exchange (loss) gain
0
0
-1
0
0
-1
0
Loss before income taxes
-22
-13
-41
-19
-10
-2
47
Benefit (provision) for income taxes
0
0
2
1
0
0
-1
Net loss
-22
-13
-39
-18
-10
-2
45
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (29 items missing)
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Assets
Cash and cash equivalents
n/a
14
15
9
17
18
68
Short term investments
n/a
10
0
0
0
0
0
Accounts receivable, net of allowance for doubtful accounts
n/a
15
14
12
12
12
15
Other receivables
n/a
0
0
0
0
7
0
Inventories
n/a
9
9
9
9
7
7
Prepaid expenses
n/a
3
2
2
2
2
2
Total current assets
n/a
51
40
33
41
46
91
Property, plant, and equipment, net
n/a
10
9
9
8
8
8
Goodwill
n/a
27
7
7
7
7
7
Intangible assets, net
n/a
20
12
10
8
6
4
Other
n/a
0
0
0
0
0
0
Total assets
n/a
109
69
59
64
68
112
Liabilities and owners' equity
Loan payable
n/a
0 0
0 0
3 3264000
3 3013000
3 3013000
2 1557000
Accounts payable - trade
n/a
8 7858000
9 9020000
8 8481000
8 8245000
9 8762000
10 9857000
Accrued liabilities
n/a
8 8188000
10 9818000
12 11776000
13 12917000
11 11297000
8 8211000
Other current liabilities
n/a
2 1683000
0 118000
0 331000
1 790000
1 886000
1 943000
Total current liabilities
n/a
18 17729000
19 18956000
24 23852000
25 24965000
24 23958000
21 20568000
Deferred taxes
n/a
3 2934000
1 938000
0 200000
0 183000
0 37000
0 0
Other liabilities
n/a
0 96000
0 128000
1 774000
2 2313000
2 1793000
2 1699000
Total liabilities
n/a
0 0
20 20022000
25 24826000
27 27461000
26 25788000
22 22267000
Commitments and contingencies
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Preferred stock
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Common stock
n/a
0 390000
0 395000
0 406000
0 443000
0 461000
0 463000
Additional paid-in capital
n/a
306 305833000
304 304358000
304 304288000
317 317160000
325 324966000
326 326288000
Less treasury stock at cost
n/a
-6 -6387000
-3 -3074000
0 0
0 0
0 0
0 0
Accumulated deficit
n/a
-215 -214914000
-254 -254183000
-272 -272420000
-282 -282397000
-285 -284682000
-239 -239396000
Accumulated other comprehensive income
n/a
4 3793000
2 1605000
2 1858000
2 1744000
2 1861000
2 2199000
Total stockholders’ equity
n/a
89 88715000
49 49101000
34 34132000
37 36950000
43 42606000
90 89554000
Total liabilities and stockholders’ equity
n/a
109 109474000
69 69123000
59 58958000
64 64411000
68 68394000
112 111821000
Remarks restated on n/a restated on Nov 30, -1 n/a restated on Oct 15, 2013 n/a restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (35 items missing)
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Net loss
-22
-13
-39
-18
-10
-2
45
Depreciation and amortization of property, plant and equipment
3
3
3
3
2
2
2
Amortization of intangible assets
2
2
2
2
2
2
2
Provision for uncollectible accounts receivable
3
4
5
4
3
2
2
Deferred income tax (benefit)
0
0
-2
-1
0
0
0
Share-based compensation charges
1
1
1
1
1
0
1
Accrual for share-based 401(k) employer match expense
1
1
1
1
1
1
1
Deferred revenue recognized
0
0
0
0
0
0
0
Foreign exchange (gain) loss
0
0
1
0
0
1
0
Impairment charges
0
0
25
0
0
0
0
Accounts receivable
-4
-7
-4
-3
-3
-2
-5
Other receivables - settlements
0
0
0
0
0
-7
7
Inventories
1
0
0
0
0
1
0
Prepaid expenses
0
0
0
0
0
0
0
Accounts payable - trade
2
1
1
-1
0
0
1
Accrued liabilities, other current liabilities and other liabilities
0
0
2
2
3
-2
-3
Total adjustments
9
5
33
8
8
-1
8
Net cash used in operating activities
-13
-8
-6
-10
-2
-4
53
Capital expenditures
-3
-1
-1
-1
-1
-2
-2
Maturities of short term investments
232
182
58
0
0
0
0
Purchases of short term investments
-214
-168
-48
0
0
0
0
Decrease in security deposits and other
0
0
0
0
0
0
0
Earn-out payment
0
0
-1
0
0
0
0
Net cash used in investing activities
15
14
7
-1
-1
-2
-2
Net proceeds from issuance of common stock
0
0
0
2
12
7
0
Proceeds from borrowings under Credit Agreement
0
0
0
13
79
89
90
Repayments under Credit Agreement
0
0
0
-10
-79
-89
-91
Installment loan payments
0
0
0
0
0
0
-1
Proceeds from the exercise of stock options
0
0
0
0
0
0
0
Net cash provided by financing activities
0
0
0
5
11
6
-2
Effect of exchange rate changes on cash and cash equivalents
0
0
0
0
0
0
0
Increase (decrease) in cash and cash equivalents
2
5
1
-6
8
1
50
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Oct 9, 2014 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,